Innate Pharma (IPHYF) Asset Utilization Ratio (2020 - 2025)
Historic Asset Utilization Ratio for Innate Pharma (IPHYF) over the last 6 years, with Q2 2025 value amounting to 0.73.
- Innate Pharma's Asset Utilization Ratio fell 9974.77% to 0.73 in Q2 2025 from the same period last year, while for Jun 2025 it was 0.73, marking a year-over-year decrease of 9974.77%. This contributed to the annual value of 0.14 for FY2024, which is 5772.34% down from last year.
- According to the latest figures from Q2 2025, Innate Pharma's Asset Utilization Ratio is 0.73, which was down 9974.77% from 0.83 recorded in Q4 2024.
- In the past 5 years, Innate Pharma's Asset Utilization Ratio registered a high of 288.29 during Q2 2024, and its lowest value of 0.06 during Q2 2022.
- Its 5-year average for Asset Utilization Ratio is 108.35, with a median of 0.83 in 2024.
- Per our database at Business Quant, Innate Pharma's Asset Utilization Ratio skyrocketed by 38482646.05% in 2023 and then plummeted by 9974.77% in 2025.
- Over the past 5 years, Innate Pharma's Asset Utilization Ratio (Quarter) stood at 0.27 in 2021, then skyrocketed by 72358.79% to 198.18 in 2022, then grew by 26.24% to 250.18 in 2023, then tumbled by 99.67% to 0.83 in 2024, then fell by 12.19% to 0.73 in 2025.
- Its Asset Utilization Ratio was 0.73 in Q2 2025, compared to 0.83 in Q4 2024 and 288.29 in Q2 2024.